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Background: Involvement of patients in decision-making about medication is currently being advocated. This study
examined (the concordance between) inflammatory arthritis patients’ preferred and perceived involvement in
decision-making in general, and in four specific decisions about Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Furthermore, this study examined how patients’ involvement is related to satisfaction about decision-making and
which factors are related to preferred roles, perceived roles and concordance.
Methods: Using a cross-sectional survey, 894 patients diagnosed with Rheumatoid Arthritis, Psoriatic Arthritis or
Ankylosing Spondylitis were sent a questionnaire which focused on medical decisions in general and on four
specific decisions: (a) starting with a traditional DMARD; (b) starting to inject methotrexate; (c) starting a biological
DMARD; and (d) decreasing or stopping a DMARD. For each decision preferred and perceived involvement in
decision-making was assessed using the Control Preference Scale. Concordance was calculated by subtracting the
scores for perceived role from scores for the preferred role. Furthermore, satisfaction with the decision process and
socio-demographic, health-related, patient-related and physician-related variables were assessed.
Results: The response rate was 58%. For all decisions, most patients (59%-63%) preferred Shared Decision-Making
(SDM). SDM was perceived frequently (26%-55%) and patients’ preferences were met in 54% of the respondents.
Yet, in some specific decisions, 26% to 54% of patients would have liked more participation. Perceiving less participation
then preferred was associated with less satisfaction with the decision-process, but perceiving more participation than
preferred was not. Our results did not reveal any meaningful models to predict preferred or perceived participation in
decision-making in general or with reference to specific decisions about DMARDs.
Conclusions: Most arthritis patients prefer to be involved in decisions about their medication and SDM is perceived
frequently. Yet, in some specific decisions patient participation can be further improved. Patients especially prefer more
participation in decision-making regarding starting a first traditional DMARD, which occurs most commonly in newly
diagnosed patients. Whereas perceiving too little participation was associated with decreased satisfaction, perceiving too
much participation was not. Therefore, rheumatologists should urge patients to participate in every medical decision.
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Medication use is central to the management of rheum-
atic diseases and medication adherence is essential for
the success of the treatment. Traditionally, decisions
about medication have been viewed from a paternalistic
perspective where the prescriber makes decisions based
on medical knowledge and the patient either complies
or does not comply with the prescribed regime (also
defined as clinician-led decision-making).
Currently, involvement of patients in decision-making
about medication is being advocated. Patient involve-
ment in decision-making is considered beneficial for
various reasons. First, the patient’s agreement with the
choice of treatment is important since the patient’s co-
operation in carrying out the treatment is essential [1].
Secondly, Shared Decision-Making (SDM) is assumed to
lead to improvement in health outcomes, such as health
status, self-management, adherence, coping behavior and
satisfaction with care [2-5], especially in chronic diseases
[6]. Finally, patients have the right to self-determination
and should thereby be empowered by information about
their diagnosis, treatment options and prognosis to make
treatment decisions that correspond with their preferences
and values [7].
Whereas patient participation is considered to be
important and beneficial, SDM can be difficult to achieve
for both doctors and patients. Doctors are often reluctant
or unprepared to involve patients in medical decisions
[8,9]. Some barriers mentioned by doctors are lack of time
and low confidence in their ability to communicate risks
effectively [10]. Patients also experience barriers, such as
unawareness of having a choice, low confidence to partici-
pate, a belief of having a lack of knowledge and un-
certainty about which questions to ask [11,12].
Furthermore, not all patients want to be actively involved
in medical decision-making. Results of previous studies
concerning patients’ preferences regarding participation in
treatment decisions show high variability [13-17], including
the field of rheumatology [18-21]. Although, there is exten-
sive literature that has examined factors (socio-demographics,
health-related, patient-related and physician-related) that
predict patients’ preferences regarding involvement, results
are inconclusive and it remains difficult to explain or predict
patient preferences [13,19,21-26]. Garfield, Francis and
Smith [25] suggest that preference regarding involvement
might vary per type of decision. Moreover, role preference
may change over time and change as health status
changes [11,13,17,19,23,27]. Thus, to pursue concordance
between patients’ preferred and actual role in decision-
making, it is essential to study patients’ preferences regard-
ing involvement and to discriminate between specific
decisions.
Compared to decisions in acute care, decisions in
chronic care are more likely to need an active patientrole in executing the decision [28]. In rheumatology, de-
cisions about medication reoccur during the process of
the disease and are likely to be revised and reversed. How-
ever, the latter does not make it easier to make a decision.
Treatment decisions have become increasingly complex
due to the many new available Disease-Modifying Anti-
Rheumatic Drugs (DMARDs). These drugs vary with
respect to approximate time to benefit, side effects and
risks, dosage, and route of administration.
Four specific decisions regarding DMARDs are particu-
larly relevant: (a) starting with traditional DMARDs; (b)
starting to inject methotrexate; (c) starting a biological
DMARD; and (d) decreasing or stopping a DMARD.
Guidelines strongly recommend early intervention with a
traditional DMARD [29-31]. The recommended trad-
itional DMARD of first choice is methotrexate, which can
be administered orally or by subcutaneous injection. In
case of intolerance or disfavour for methotrexate, other
traditional DMARDs are good alternatives. In the
Netherlands, therapy with a biological DMARD can only
be prescribed to patients with at least moderate disease
activity and in whom treatment with at least 2 traditional
DMARDs has failed. The decision to decrease or stop
medication occurs when the disease is in remission or
when side effects are presented.
Although it seems the management of inflammatory
arthritis is strongly protocolled, involving patients in
decision-making about DMARDs is important, as some
of the DMARDs can have serious side effects and the
route of administration (orally, subcutaneous injection
or intravenous injection) may have a large impact on pa-
tients’ daily lives. Thus, to choose the best treatment is a
process concerning clinical aspects, but also patients’ pref-
erences need to be considered. After all, these decisions
require an active patient role in carrying out the decision
and adherence is essential for the success of the
treatment.
More knowledge about inflammatory arthritis patients’
preferred level of involvement could lead to rheumatolo-
gists and other caregivers anticipating on this and make it
easier to pursue the preferred level of patient involvement.
We expect patients to be more satisfied with the decision-
process if concordance is reached between the preferred
and perceived level of participation. Whereas a few studies
have examined inflammatory arthritis patients’ preferred
and/or perceived role in medical decision-making in gen-
eral, to the best of our knowledge there is no data compar-
ing patients’ preferred and perceived role in specific
decisions. Therefore, this study focused on inflammatory
arthritis patients’ preferred and perceived participation in
various decisions related to the use of DMARDs. We studied
the concordance between preferred and perceived roles and
the perceived satisfaction about the decision process. Fur-
thermore, we examined which factors (socio-demographic,
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associated with the preferred and perceived roles.Methods
Sample and setting
We focused our cross-sectional survey on patients with
rheumatic diseases who were likely to use DMARDs: pa-
tients diagnosed with Rheumatoid Arthritis (RA), Psoriatic
Arthritis (PsA) or Ankylosing Spondylitis (AS). Patients
were recruited from two hospitals in the Netherlands:
Medisch Spectrum Twente (MST) and Ziekenhuisgroep
Twente (ZGT). Patients were selected with use of the
electronic hospital records. First, a random sample of 965
patients (500 from MST, 465 from ZGT) who met the
following criteria was selected: (a) consulted their rheuma-
tologist in the past year; and (b) were diagnosed with RA,
PsA or AS. The list of selected patients was then discussed
with the treating rheumatologist. Based upon this, 71
patients were excluded because either the patient (1) was
deceased, (2) had an incorrect diagnosis registered in the
electronic hospital record, or (3) was not able to complete
a Dutch written questionnaire (subjective interpretation
by the rheumatologist). In total 894 eligible patients were
sent a questionnaire by mail, accompanied by a letter of
invitation from their rheumatologist and an informed
consent form. The patients were asked to return the filled
out questionnaires and the informed consent form to the
University of Twente using a prepaid envelope. After three
weeks a reminder was sent.
The study did not need approval of the ethical review
board according to the Dutch Medical Research Involving
Human Subjects Act (WMO); only (non-intervention)Table 1 Description of decisions as provided in questionnaire
Decision Description
Starting traditional
anti-rheumatic drugs.
The following questions concern starting tradition
reduce joint damage. They decrease disease activ
prevent further joint damage.
Examples: methotrexate (Emthexate®, Ledertrexate®)
hydroxychloroquine (Plaquenil®), penicillamine (Gero
(Arava®).
Starting to inject. Medication can be administered in various ways.
subcutaneous injection. Methotrexate (Emthexate
subcutaneous injection. The following questions c
Beware: these questions only concern methotrexate
Starting biologic
anti-rheumatic drugs.
The following questions concern starting biologic
are administered by subcutaneous injection or dir
arthritis by inhibiting mediators of inflammation, s
Examples: Adalimumab (Humira®), Etanercept (Enbr
Decreasing or stopping
anti-rheumatic drugs.
For various reasons medication can be decreased
doing so well that the dosage may be decreased
The following questions concern decreasing or st
Beware: these questions only concern your anti-rheustudies with a high burden for patients have to be
reviewed.
Measures
Standardized scales were used as much as possible. If
there was no Dutch scale available, scales were translated
using the forward-backward procedure [32].
The questionnaire contained 65 questions and focused
on medical decisions in general and on four specific deci-
sions: (a) starting with a traditional DMARD; (b) starting
to inject methotrexate; (c) starting a biological DMARD;
and (d) decreasing or stopping medication. To make it
easier for patients to remember the decisions addressed in
the questionnaire, a short description of each decision was
given including purpose, route of administration and gen-
eric and brand medicine names (see Table 1). For each de-
cision patients were asked (1) whether they had ever faced
the decision, and if relevant, patients were asked to think
of the first time they faced the decision. Then they were
asked (2) what role they had perceived, (3) what the out-
come of the decision had been (e.g. starting or not starting
with the suggested medication), and (4) if they were
satisfied with the decision-making process. Subsequently,
all patients (including patients who had never faced the
decision) were asked what role they preferred to have.
Furthermore, socio-demographic, health-related, physician-
related and patient-related variables were questioned.
Preferred and perceived participation and concordance
Preferred and perceived roles in medical decision-making
were assessed with the ‘Control Preference Scale’ (CPS)
[33] adapted by Garfield, et al. [19]. Questions about the
perceived role started with “In your opinion, who decided(translated from Dutch)
al anti-rheumatic drugs, also called traditional DMARDs. These drugs can
ity: they ease pain and rigor and on the long term
, sulfasalazine (Salazopyrine®); gold (Tauredo®, Ridaura®),
dyl®), azathioprine (Imuran®), ciclosporine (Neoral®) and leflunomide
Most drugs are administered orally as tablets. Another way is by
®, Ledertrexate®) is available as tablet, but can also be administered by
oncern starting subcutaneous methotrexate injections.
and not other drugs that may be administered by subcutaneous injection.
anti-rheumatic drugs, also called biologic DMARDs. Biologic DMARDs
ectly into a vein. Biologic DMARDs aim to reduce
uch as TNF and Interleukine-1.
el®), Infliximab (Remicade®), Anakinra (Kineret®).
or even stopped. This may be due to side effects or because you are
.
opping anti-rheumatic drugs.
matic drugs and not pain medication or other drugs.
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you are informed about the benefits and risks, who should
finally decide about …”. Response categories were: “The
rheumatologist” (1), “Mostly the rheumatologist” (2), “The
rheumatologist and me together” (3), “Mostly me” (4), and
“Me alone” (5). Further, we recalculated the CPS scores to 3
levels: doctor (1–2), shared (3) and patient (4–5), as vali-
dated by Degner [33]. Concordance was calculated by sub-
tracting the original perceived CPS scores from the original
preferred CPS scores. The results ranged from −4 to 4 and
were then coded into 3 levels: too little participation (<0),
enough participation (0) and too much participation (>0).Satisfaction
For each specific decision, satisfaction with the decision-
making process was assessed with one item ‘How satisfied
are you about how this decision was made?’ using a five-
point Likert scale (very unsatisfied (1) – very satisfied (5)).
Socio-demographic variables included sex, age, marital
status, education (low, medium, high), income (low,
medium and high) and work status (employed vs. un-
employed, volunteer, student, retired, or homemaker).
Health related variables included diagnosis (RA, PsA or
AS), time since diagnosis (<1 year, 1–5 years, 5–10 years,
or >10 years) and health-related quality of life. Health-
related quality of life was assessed with the SF-12, version
2 [34]. Standardized scores were calculated for the
physical and mental well-being varying from 0 (poor well-
being) to 100 (excellent well-being), with a mean of 50
and a standard deviation of 10 in the general population
of the United States [34].Patient-related variables
Need for information was assessed with a subscale of the
Autonomy Preference Index (API) [23]. The API consists
of 8 items and patients respond on a five-point Likert
scale. Response choices range from 0 (strongly disagree)
to 4 (strongly agree). Sum scores were linearly adjusted to
range from 0 (no need for information) to 100 (strongest
possible need for information). Internal consistency was
adequate (Cronbach’s α = 0.66).
Patients' self-efficacy in obtaining medical informa-
tion and attention to their medical concerns by physi-
cians was assessed using the ‘Perceived Efficacy In
Patient-Physician Interaction’ (PEPPI) scale [35]. The
PEPPI consists of 10 items, each beginning with ‘How
confident are you in your ability to…’ and using
response options 1 (not at all confident) to 5 (very
confident). Scores on the 10 items were added for each
patient to acquire a total score, with higher scores
indicating more self-efficacy. Internal consistency was
good (Cronbach’s α = 0.91).Physician-related variables
Characteristics of consultations with the rheumatologist
included three variables: 1) frequency of visits in the last
year (once a year, 2–4 times a year, more than 4 times a
year), 2) having a regular rheumatologist (‘How often do
you consult the same rheumatologist’) using a five-point
Likert scale (always – never) and 3) duration of the
relationship with the rheumatologist (in years).
Perceived trust in the physician and emotional support
from the physician were assessed with 2 subscales of the
‘Cologne Preference Questionnaire’ (CPQ) [36,37]. Per-
ceived trust in the physician was measured with 3 items.
Patients’ evaluation of emotional support was assessed
with 4 items. Response choices range from 1 (strongly dis-
agree) to 4 (strongly agree). Scale scores were computed
for each scale by the mean of the items. Both scales range
from 1 to 4 with a lower score indicating lower trust or
lower emotional support. Internal consistency of both
scales were good (Cronbach’s α = 0.93 and α = 0.85,
respectively).
Prior to inclusion, we performed a pilot test among pa-
tients (n = 8) to assess the readability and acceptability of
time to complete the questionnaire. The test showed that
the questionnaire took about 20–25 minutes to complete,
which was acceptable according to the participants. Minor
textual adjustments were made following the results of the
pilot test.
Statistical analysis
To detect differences in the distributions of (concordance
between) preferred and perceived participation across
decisions, chi-square tests were performed. Chi-square
tests were also used to detect differences in the distribu-
tion of preferred participation between respondents who
had faced the decision versus respondents who had not
faced the decision.
The Kruskal Wallis test was used to compare differences
in satisfaction between groups with different levels of
perceived participation and with different levels of con-
cordance. Next, a post hoc Mann–Whitney U test with
Bonferroni correction was used to test which groups were
significantly different from each other.
To examine which factors are associated with preferred
role and perceived role we performed multivariate binary
logistic regression analyses. We predicted the preference
for and perception of shared decision-making compared
to clinician-led decision-making. The relationship with
patient-led decision-making has not been analysed be-
cause of the too small numbers of patients preferring or
perceiving this (frequencies ranging from 6 to 76, depend-
ing on the type of decision) relative to the number of
predictors (n = 13). We included the following predictors:
age, sex, education, employment, years since diagnosis,
physical and mental well-being, self-efficacy in patient-
Table 2 Demographic, health-related, physician-related
and patient-related characteristics (n = 519)*
Variables Categories Value
Socio-demographic
variables
Age, years 56 ± 12
Women, no. (%) 285 (59)
Married/living with a
partner, no. (%)
391 (82)
Education, no. (%) Low (<12 years) 155 (33)
Medium (12 – 16 years) 220 (47)
High (>16 years) 94 (20)
Family income, no. (%) Low (< €28.500/year) 114 (31)
Medium (€28.500 -
€34.000/year)
112 (31)
High (> €34.000/year) 139 (38)
Fulltime and part time
employed, no. (%)
198 (45)
Health-related variables
Diagnosis (n,%) Rheumatoid Arthritis 307 (63)
Psoriatic Arthritis 120 (25)
Ankylosing Spondylitis 58 (12)
Years since diagnosis,
no. (%)
<1 19 (5)
1–5 82 (21)
6–10 159 (40)
>10 139 (35)
Well-being (SF-12)
(range 0–100)
Physical 39 ± 10
Mental 49 ± 10
Patient-related
Self-efficacy in patient-provider
interaction (PEPPI) (range 10–50)
39.9 ± 4.2
Need for information (API)
(range 0–100)
71.7 ± 10.3
Physician-related variables
Frequency of visits in the last
year, no. (%)
once a year 75 (14.7)
2–4 times a year 344 (67.5)
>4 times a year 89 (17.5)
Duration of relationship with
rheumatologist (years)
7 (7)
Almost every visit the same
rheumatologist, no. (%)
501 (97%)
Trust in physician (CPQ) (range
1–4)
3.48 ± .49
Emotional support of physician
(CPQ) (range 1–4)
3.13 ± .49
*Values are the mean ± SD (range) unless otherwise indicated.
SF12 = 12-Item Short Form Health Survey; CPQ = Cologne Preference
Questionnaire; PEPPI = Perceived Efficacy in Patient-Provider Interaction;
API = Autonomy Preference Index.
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visits in the last year, duration of relationship with the
rheumatologist, trust in physician and emotional support
of physician.
Results
Patient characteristics
We received 519 completed questionnaires (response rate
58%). The sample of respondents was heterogeneous in
regard to socio-demographic and health related variables
(Table 2). The mean score for physical wellbeing was 39,
somewhat lower than that of the US general population
(50), but similar to that of the US RA population [34]. The
mean score for mental wellbeing was similar to that in the
general population. Most respondents visited their
rheumatologist 2–4 times per year (n = 344; 67.5%) and
saw the same rheumatologist at almost every visit
(n = 501; 97%).
Concordance of preferred and perceived participation
Across decisions, most respondents (59-63%) preferred to
share decisions about their treatment with their doctor,
though a small but considerable group wanted the doctor
to decide (Table 3). We found no significant differences
between respondents who had faced the decision versus
respondents who had not faced the decision. A small,
though statistically significant (Chi-Square = 15.22; df = 6;
P = 0.02) difference in the distributions of preferred par-
ticipation was found between the four decisions: regarding
the decision whether or not to start injecting MTX, rela-
tively more respondents preferred to decide by themselves
(15% versus 9-11% for the other decisions). The distribu-
tions of role preference did not significantly differ between
the other three decisions.
With regard to the perceived roles, the majority felt that
decisions were often made by doctor and patient together
(Table 3). Yet, a considerable number of patients felt that
ultimately the doctor made the final decision. We found a
significant difference between the distributions of perceived
participation between the four decisions (Chi-Square =
139.56; df = 6; P < 0.001). Some decisions stand out: 72% of
the respondents perceived that the decision to start using a
traditional DMARD was made by the doctor alone, as
opposed to 38% – 44% for the other decisions. On the
other hand, for the decision to start injecting methotrexate
or to decrease or stop medication, a considerable number
of patients felt they had made the decision by themselves
(17% and 24%, respectively).
Table 4 shows the data on concordance of the preferred
and perceived roles. For 43% - 62% of the patients, a
match was established between the preferred and per-
ceived roles. A considerable group (26% - 54%) perceived
“too little” participation, compared to their preference.
Again, there was considerable and significant variation
Table 3 Preferred and perceived role in medical decision-making
Decision Preferred role1 Perceived role1
Doctor (1) Shared (2) Patient (3) Valid N Doctor (1) Shared (2) Patient (3) Valid N
MDM in general 31% 61% 8% 504 43% 55% 1% 506
Traditional DMARD 32% 59% 10% 491 72% 26% 2% 368
Injecting MTX 25% 60% 15% 466 43% 40% 17% 162
Biologic agent 26% 63% 11% 471 44% 50% 6% 149
Decrease/stop 30% 61% 9% 489 38% 38% 24% 314
MDM =Medical Decision-making; DMARD = Disease Modifying Anti-Rheumatic Drug; MTX =methotrexate.
1Data of perceived role included respondents who had ever faced the decision; data of preferred role included all respondents.
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more than half of the respondents perceived too little par-
ticipation with the decision to start using a traditional
DMARD and almost one third perceived too much par-
ticipation in deciding to decrease or stop their medication.
Satisfaction with the decision process
Most respondents (83% – 89%) felt “satisfied” or “very sat-
isfied” with the decision process in general and for each
specific decision. There were however significant differ-
ences in satisfaction between the three levels of perceived
participation (doctor, shared, patient) (Table 5). For most
decisions, patients were more satisfied when they partici-
pated in decision-making.
Regarding the relationship between satisfaction and con-
cordance, we expected that patients who achieved con-
cordance (“enough participation”) would be more satisfied
than those who perceived “too little” or “too much”
participation. Our results indeed revealed that, for most
decisions, patients who perceived “too little” participation
were significantly less satisfied. Yet, getting “too much”
participation did not decrease satisfaction. Overall, our
results suggest that perceiving “too much participation” is
not related to less satisfaction.
Factors associated with preferred and perceived roles
When analyzing factors associated with the preference for
and perception of SDM compared to clinician-led decision-
making, only a few significant weak relationships were
found in the multivariate binary logistic regression analysis.
For the preference for SDM in general medical decision-
making only age (OR = 0.960; 95% CI 0.935 - 0.985;Table 4 Concordance between preferred and perceived role
Too little participation
MDM in general (n = 496) 29%
Traditional DMARD (n = 330) 54%
Injecting MTX (n = 137) 29%
Biologic agent (n = 129) 30%
Decrease/stop (n = 303) 26%
MDM =Medical Decision-making; DMARD = Disease Modifying Anti-Rheumatic Drugs; Mp = 0.002) and education (OR = 1.462; 95% CI 1.007 - 2.121;
p = 0.046) were significant predictors; meaning that youn-
ger and higher educated patients more often prefer SDM
than clinician-led decision-making. However, the goodness
of fit of the total model was small (Nagelkerke Pseudo R2 =
0.102; p = 0.028). No significant relationships were found
between preferred role and any of the other variables
included in the regression analysis.
For the perception of SDM in general medical decision-
making only physical wellbeing (OR = 0.973; 95% CI 0.949 -
0.998; p = 0.036) and emotional support (OR = 2.232; 95%
CI 1.172 - 4.251; p = 0.015) were significant predictors;
meaning that patients with physical problems and who
perceive more emotional support from their attending
physician more often perceive SDM than clinician-led
decision-making. However again, the goodness of fit of the
total model was small (Nagelkerke Pseudo R2 = 0.130;
p = 0.001). None of the other variables that were included
in the regression analysis were significantly related to the
perception of SDM.
We also analyzed factors associated with preference
for and perception of SDM for specific decisions (data
not shown), but no clear pattern arose and relationships
were small (R2’s for all models < 0.14).Discussion
Our study shows that the majority of patients with RA,
PsA and AS prefer to share decisions about medication,
although a small, but significant group still wants the doc-
tor to decide. These results are in line with other studies
in rheumatology [18-21] and other chronic diseases [38].Enough participation Too much participation
61% 10%
43% 4%
56% 14%
62% 8%
46% 28%
TX =methotrexate.
Table 5 Satisfaction with the decision process1 by perceived role and by concordance
Perceived role Concordance
Doctor Shared Patient P2 Too little participation Enough participation Too much participation P3
Mean Mean Mean Mean Mean Mean
(SD) (SD) (SD) (SD) (SD) (SD)
MDM in general (N = 502) 4.0a 4.2a 4.0 .04* 3.9ab 4.2a 4.4b .00**
(0.8) (0.7) (0.6) (0.8) (0.7) (0.5)
(N = 218) (N = 278) (N = 6) (N = 142) (N = 302) (N = 52)
Traditional DMARD (N = 332) 3.9a 4.2a 4.3 .00** 3.8ab 4.1a 4.3b .00**
(0.7) (0.6) (0.5) (0.6) (0.6) (0.7)
(N = 234) (N = 90) (N = 8) (N = 177) (N = 141) (N = 12)
Injecting MTX (N = 137) 3.8a 4.2a 4.0 .02* 3.7ab 4.1a 4.3b .00**
(0.9) (0.6) (0.7) (0.8) (0.7) (0.7)
(N = 53) (N = 59) (N = 25) (N = 41) (N = 76) (N = 20)
Biologic agent (N = 131) 4.0 4.3 4.2 .16 4.1 4.3 3.8 .31
(0.8) (0.6) (1.6) (0.9) (0.7) (1.2)
(N = 58) (N = 67) (N = 6) (N = 39) (N = 80) (N = 10)
Decrease/stop (N = 304) 3.9a 4.1ab 3.8b .00** 3.8a 4.1ab 3.8b .00**
(0.8) (0.6) (0.8) (0.8) (0.7) (0.8)
(N = 115) (N = 115) (N = 74) (N = 80) (N = 139) (N = 84)
MDM =Medical Decision-making; DMARD = Disease Modifying Anti-Rheumatic Drug; MTX =methotrexate.
1ranging from 1 – 5 in which higher scores indicate more satisfaction.
2p-levels for differences between doctor, shared and patient, tested with the Kruskal-Wallis test.
3p-levels for differences between too little, enough and too much participation, tested with the Kruskal-Wallis test.
a or bDistributions are significant different from each other (post hoc test with Mann Whitney with Bonferroni correction).
*Significant on the .05 level.
**Significant on the .01 level.
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the field of rheumatology that examined the concordance
between preferred and perceived roles. Our study shows
that, in rheumatologic outpatient care, Shared Decision-
Making is perceived frequently and patients’ preferences
are met in over half of the patients. However, the amount
of concordance varied significantly between decisions; a
considerable group (on average 34%) still wanted more
participation than they perceived. These results are
comparable to studies examining other conditions, such
as cancer and asthma where concordance levels varying
from 34% - 66% have been reported [14,22,27,39-41].
We also examined the relationship between concord-
ance in patient participation and patients’ satisfaction. We
expected that patients would be less satisfied with the
decision process if they perceived either too little or too
much participation. However, our results suggested that
patients are only less satisfied if they perceive too little
participation. If patients perceived more participation than
preferred, they were still highly satisfied. Although many
studies have shown that SDM can improve satisfaction
[2-6], to our knowledge it has not been previously
reported that offering a greater than preferred level of
participation is not related to diminished satisfaction, but
offering too little is. These findings implicate that patientsshould be invited to participate in medication decision-
making by their rheumatologist at all times.
Previous studies on patient involvement in medical
decision-making have mostly looked at decision-making
in general. Our study discriminated between medical
decision-making in general and four specific decisions
that are common in rheumatology. Contrary to our ex-
pectations, we found no relevant variety in role prefer-
ence between these decisions. It seems to be that role
preference in decisions about medication for rheumatic
diseases is rather stable.
Although we did not find any relevant differences in
the distribution of role preferences between the four de-
cisions, we did find differences in the distribution of
perceived role and concordance. Two decisions stand
out: the decision to start using a traditional DMARD
and the decision to decrease or stop a DMARD. With
this first decision, the majority of patients (72%) per-
ceived that the doctor decided and in contrast to the
other decisions, more than half of the patients (54%) did
not achieve their preferred level of participation. An
explanation for this finding might be that in the setting
of starting a traditional DMARD for the first time there
is lack of awareness of choice and too little time for pa-
tients to participate. The decision to start a traditional
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commonly in newly diagnosed patients. The current
guidelines for early arthritis recommend starting with ag-
gressive treatment as soon as possible, with methotrexate
being the recommended drug of first choice. It is plausible
that patients initially only receive one treatment recom-
mendation and are not aware of alternative treatment
options. Upon receiving the diagnosis, the patient needs
to process a lot of information (about the influence of this
chronic disease on daily life, starting aggressive treatment,
etc.) in a short time. Not being aware of having a choice,
little time, and/or an overload of information may be a
barrier for patient involvement [11,12]. In clinical practice,
extra time (to think and to create awareness of choice)
needs to be considered when dealing with newly diag-
nosed patients that need to make decisions about starting
with a traditional DMARD. Additionally, patients need to
be urged to participate to arrive at a decision concordant
with their values. These actions may not only enhance
patients’ satisfaction, it may also increase patients’ self-
efficacy in being adherent to medication use [42-45].
The decision to decrease or stop medication stands out
because, in contrast to the other decisions, relatively many
respondents (24%) felt they had made this decision by
themselves. Moreover, a large group perceived too much
participation in this decision. The decision to decrease or
stop medication is different from the other decisions, be-
cause it occurs when the disease is in remission or when
side effects are presented. It is possible that patients are
more strongly invited to participate in the decision to
decrease or stop their medication, because it is more pref-
erence sensitive. Previous studies have shown that patients
fear returning symptoms (in the case of remission) or
unknown side effects (when changing therapy) [46,47].
More research is necessary to clarify why patients feel they
are too much involved in the decision to decrease or stop
medication. These studies should discriminate between
decisions to decrease or stop medication in case of remis-
sion or to decrease or stop medication when side effects
are presented.
The final aim of this study was to examine for each
decision which factors were associated with preferred and
perceived roles. Although we assessed many possible vari-
ables, our results did not reveal any meaningful models to
predict preferred or perceived participation in decision-
making in general or with reference to specific decisions
about DMARDs. In rheumatology, only a few studies have
examined associated factors for preferred and perceived
roles and those results are inconclusive [18-21,48]. For
example, female gender was significantly associated with
higher preferences for involvement in decision-making
in one study [20], but not others [18,19]. Likewise,
younger age has been reported as a significant predictor
of preference for involvement [18-20], but in our datawe only found weak correlations and the results varied per
decision. As far as we know, only one previous study has
examined associations with perceived involvement in
rheumatology [48]. Although this study found several sig-
nificant associated factors, the presented odds ratios for
high involvement were low or with a high confidence
interval (indicating a low level of precision of the odds
ratio) [49]. Results of studies using other populations were
also inconclusive [39,40,50-54]. Our findings imply that it
remains difficult to identify subgroups that are more in
need of being involved. However, as our results revealed
that too much participation is not related to diminished
satisfaction, we can recommend that caregivers facilitate
patient participation in all of their patients. Therefore we
suggest training in SDM should be emphasized in educa-
tional programs of rheumatologists.
A strength of this study is its large representative sample
of patients to examine preferred roles, perceived roles,
concordance and satisfaction in various decisions regard-
ing medication use in rheumatology. Due to some limita-
tions of the study, some caution is necessary when
interpreting our results. First, due to sizable non-response,
our results might be slightly biased. Although we had a
response rate of 58%, selection bias might have occurred.
It is possible that patients who have no need of partici-
pating in medical decision-making, are less interested in
(responding to questionnaires about) patient participation.
Second, due to limited resources we chose to conduct a
retrospective study and therefore it is possible that recall
bias occurred. We questioned patients about the first time
they faced these decisions. Some of these decisions may
have occurred years before the study. Even though we did
not find any significant differences in preferred and per-
ceived role between patients with a long (>1 year) and
short (<1 year) illness duration, the limitation of possible
recall bias remains. We therefore recommend a prospect-
ive study which questions patients at the time of the deci-
sion. Third, no patient representatives were included in
our research group as has been recently recommended
[55]. Patient representatives can provide valuable sugges-
tions about which aspects to include in the questionnaires
and the interpretation of results. Yet, as the current study
is part of a larger project to develop a Patient Decision
Aid (PtDA) for anti-rheumatic drugs in which patients
were repeatedly and extensively involved in various re-
search and design activities, we feel that we have included
patient perspectives to at least some extend.
Conclusions
In conclusion our study shows that arthritis patients
appreciate being involved in decisions about their medica-
tion and that shared decision-making is perceived
frequently in rheumatology outpatient care. Yet, patient
participation can be further improved, particularly in
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the first time. As our results revealed that too much
participation is not related to diminished satisfaction, we
recommend assessing patients’ preferred and perceived
role in medical decision-making regularly and invite
patients to participate in every decision. Moreover, we
recommend rheumatologists and other caregivers to con-
sider extra time for patients to create awareness of choice
and to process all the information, especially when dealing
with newly diagnosed patients that need to make decisions
about initiating a traditional DMARD.
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